Cargando…

Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH) is a rising health challenge, with no approved drugs. We used a computational drug repositioning strategy to uncover a novel therapy for NASH, identifying a GABA-B receptor agonist, AZD3355 (Lesogaberan) previously evaluated as a therapy for esophageal reflux. AZ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharya, Dipankar, Becker, Christine, Readhead, Benjamin, Goossens, Nicolas, Novik, Jacqueline, Fiel, Maria Isabel, Cousens, Leslie P., Magnusson, Björn, Backmark, Anna, Hicks, Ryan, Dudley, Joel T., Friedman, Scott L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531016/ https://www.ncbi.nlm.nih.gov/pubmed/34675338 http://dx.doi.org/10.1038/s41598-021-99008-2

Ejemplares similares

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

Antitussive effects of the peripherally restricted GABA(B) receptor agonist lesogaberan in guinea pigs: comparison to baclofen and other GABA(B) receptor-selective agonists
por: Canning, Brendan J, et al.
Publicado: (2012)

Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication
por: Tian, Jide, et al.
Publicado: (2017)

3,3,5,5-Tetramethyl-r-2,c-6-diphenylpiperidin-4-one
por: Govindaraju, C., et al.
Publicado: (2012)

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study
por: Miner, Philip B, et al.
Publicado: (2014)

A Network-Biology Informed Computational Drug Repositioning Strategy to Target Disease Risk Trajectories and Comorbidities of Peripheral Artery Disease
por: Shameer, Khader, et al.
Publicado: (2018)

Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals
por: Lim, Wen Hui, et al.
Publicado: (2022)

Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales
por: Carter, James K., et al.
Publicado: (2021)

A double-blind randomised placebo-controlled trial investigating the effects of lesogaberan on the objective cough frequency and capsaicin-evoked coughs in patients with refractory chronic cough
por: Badri, Huda, et al.
Publicado: (2022)

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2
por: Bhattacharyya, Dipankar
Publicado: (2020)

Synthesis of C‐14 labeled GABA(A) α2/α3 selective partial agonists and the investigation of late‐occurring and long‐circulating metabolites of GABA(A) receptor modulator AZD7325
por: Artelsmair, Markus, et al.
Publicado: (2018)

Transcriptomic and phenotype analysis revealed the role of rpoS in stress resistance and virulence of a novel ST3355 ESBL-producing hypervirulent Klebsiella pneumoniae isolate
por: Zhou, Yi, et al.
Publicado: (2023)

Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning
por: Shameer, Khader, et al.
Publicado: (2017)

1,1-(Biphenyl-2,2′-diyldioxy)-3,3,5,5-tetrakis(4-bromomethylphenoxy)cyclotriphosphazene
por: Han, Rui, et al.
Publicado: (2011)

3355 The CTSA Institutional website: A higher purpose - Researcher use of institutional Clinical and Translational Science Award (CTSA) website content to assess or promote NCATS CTSA Program Goals.
por: Tafuto, Barbara Ann
Publicado: (2019)

Lip repositioning
por: Gaddale, Reetika, et al.
Publicado: (2014)

2,2,4,4-Tetraphenyl-1,3-bis(3,3,5,5-tetramethyl-1,1-diphenyl-5-vinyltrisiloxan-1-yl)cyclodisilazane
por: Lv, Zhen, et al.
Publicado: (2011)

3,3,5,5-Tetramethyl-3,5-disila-4,10-dioxatetracyclo[5.5.1.0(2,6).0(8,12)]tridecane-9,11-dione
por: Sheng, Peng-Peng, et al.
Publicado: (2009)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
por: CRAFTER, CLAIRE, et al.
Publicado: (2015)

Buccinator muscle repositioning
por: Baghele, Om N.
Publicado: (2012)

Repositioning Drugs for Psychiatry
por: Akhondzadeh, Shahin
Publicado: (2020)

Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning
por: Adasme, Melissa F., et al.
Publicado: (2020)

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
por: Zhu, Sha, et al.
Publicado: (2022)

GABA and the GABA(A) Receptor
por: Mihic, S. John, et al.
Publicado: (1997)

Effect of Repositioning Aids and Patient Weight on Biomechanical Stresses When Repositioning Patients in Bed
por: Wiggermann, Neal, et al.
Publicado: (2020)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

AZD-1222: Rhabdomyolysis: case report
Publicado: (2022)

AZD-1222: Polyarthralgia: case report
Publicado: (2021)

Azd-1222: Myelitis: case report
Publicado: (2022)

Azd-1222: Thrombocytopenia: case report
Publicado: (2022)

PI3K inhibitors protect against glucocorticoid-induced skin atrophy
por: Agarwal, Shivani, et al.
Publicado: (2019)

Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin
por: Baida, Gleb, et al.
Publicado: (2020)

Drug repositioning for personalized medicine
por: Li, Yvonne Y, et al.
Publicado: (2012)

Network mirroring for drug repositioning
por: Park, Sunghong, et al.
Publicado: (2017)

Drug Repositioning for COVID-19
por: Benavides-Cordoba, Vicente
Publicado: (2020)

GREP: genome for REPositioning drugs
por: Sakaue, Saori, et al.
Publicado: (2019)

Transcriptome-Guided Drug Repositioning
por: Arakelyan, Arsen, et al.
Publicado: (2019)

Drug Repositioning in Friedreich Ataxia
por: Rufini, Alessandra, et al.
Publicado: (2022)

Cartilaginous Dorsum Repositioning Technique
por: Azimov, Gorkhmaz
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gsd0e5ntk6g0qbej92n34rg96s